Drugs / RO7428731
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05187624 | Apr 2022 → May 2025 | glioblastoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7428731 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05187624 ↗ |
| Route | Intravenous | “intravenously (IV)” NCT05187624 ↗ |